血管紧张素转换酶抑制剂与血管紧张素受体阻滞剂联合治疗——未来的考量
Combination ACE inhibitor and angiotensin receptor blocker therapy - future considerations.
作者信息
Sica Domenic A
机构信息
Department of Medicine, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University Health System, Richmond, VA 23298-0160, USA.
出版信息
J Clin Hypertens (Greenwich). 2007 Jan;9(1):78-86. doi: 10.1111/j.1524-6175.2007.6359.x.
Abstract
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are regularly prescribed for the management of hypertension. Each of these drug classes has also been shown to provide survival benefits for patients with heart failure, proteinuric chronic kidney disease, and/or a high cardiac risk profile. The individual gains seen with each of these drug classes have led to speculation that their combination might offer additive if not synergistic outcome benefits. The foundation of this hypothesis, although biologically possible, has thus far not been sufficiently well proven to support the everyday use of these 2 drug classes in combination. Additional outcomes trials, which are currently proceeding to their conclusion, may provide the necessary proof to support an expanded use of these 2 drug classes in combination.
摘要
血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂常用于治疗高血压。这两类药物还被证明对心力衰竭、蛋白尿性慢性肾病和/或高心脏风险的患者有生存益处。这两类药物各自带来的益处引发了一种推测，即它们联合使用可能会带来相加甚至协同的疗效。尽管从生物学角度来看这一假设是有可能成立的，但迄今为止尚未得到充分证实，无法支持这两类药物联合用于日常治疗。目前正在进行的其他疗效试验可能会提供必要的证据，以支持扩大这两类药物联合使用的范围。
相似文献
1
Combination ACE inhibitor and angiotensin receptor blocker therapy - future considerations.血管紧张素转换酶抑制剂与血管紧张素受体阻滞剂联合治疗——未来的考量
J Clin Hypertens (Greenwich). 2007 Jan;9(1):78-86. doi: 10.1111/j.1524-6175.2007.6359.x.
2
Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?肾素-血管紧张素系统抑制对靶器官保护的作用：我们能否做得更好？
Clin Ther. 2007 Sep;29(9):1803-24. doi: 10.1016/j.clinthera.2007.09.019.
3
Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension.高血压中血管紧张素转换酶抑制与血管紧张素受体阻滞剂联合应用的系统评价
Hypertension. 2005 May;45(5):880-6. doi: 10.1161/01.HYP.0000161880.59963.da. Epub 2005 Apr 4.
4
The practical aspects of combination therapy with angiotensin receptor blockers and angiotensin-converting enzyme inhibitors.血管紧张素受体阻滞剂与血管紧张素转换酶抑制剂联合治疗的实际应用
J Renin Angiotensin Aldosterone Syst. 2002 Jun;3(2):66-71. doi: 10.3317/jraas.2002.020.
5
Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?血管紧张素转换酶抑制剂在高血压中的应用：用还是不用？
J Am Coll Cardiol. 2018 Apr 3;71(13):1474-1482. doi: 10.1016/j.jacc.2018.01.058.
6
Recent changes in the landscape of combination RAS blockade.联合RAS阻断领域的近期变化。
Expert Rev Cardiovasc Ther. 2009 Nov;7(11):1373-84. doi: 10.1586/erc.09.127.
7
Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial.奥美沙坦联用对慢性心力衰竭高血压患者的临床影响：奥美沙坦治疗稳定型心力衰竭高血压患者中血管紧张素受体阻滞剂的补充益处（SUPPORT）试验
Eur Heart J. 2015 Apr 14;36(15):915-23. doi: 10.1093/eurheartj/ehu504. Epub 2015 Jan 30.
8
Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.1型血管紧张素II受体阻滞剂与血管紧张素转换酶抑制剂治疗高血压的比较。
J Hypertens Suppl. 1997 Dec;15(6):S31-6. doi: 10.1097/00004872-199715066-00007.
9
Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2.使用血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂疗法降低高危患者心血管事件的发生率：第2部分。
Prev Cardiol. 2008 Fall;11(4):215-22. doi: 10.1111/j.1751-7141.2008.00004.x.
引用本文的文献
1
Angiotensin II Receptor Blockers and Arrhythmias in Ventricular Hypertrophy.血管紧张素II受体阻滞剂与心室肥厚中的心律失常
J Am Heart Assoc. 2022 Aug 2;11(15):e026634. doi: 10.1161/JAHA.122.026634. Epub 2022 Jul 19.
2
Angiotensin Converting Enzyme Regulates Cell Proliferation and Migration.血管紧张素转换酶调节细胞增殖和迁移。
PLoS One. 2016 Dec 19;11(12):e0165371. doi: 10.1371/journal.pone.0165371. eCollection 2016.
3
Randomized study to compare valsartan +/- HCTZ versus amlodipine +/- HCTZ strategies to maximize blood pressure control.比较缬沙坦±氢氯噻嗪与氨氯地平±氢氯噻嗪策略以最大程度控制血压的随机研究。
Vasc Health Risk Manag. 2009;5:883-92. doi: 10.2147/vhrm.s8062. Epub 2009 Nov 2.
4
Direct renin inhibition--commonly asked questions.直接肾素抑制——常见问题
J Clin Hypertens (Greenwich). 2008 Nov;10(11):871-5. doi: 10.1111/j.1751-7176.2008.00039.x.
本文引用的文献
1
Acute renal failure during lisinopril and losartan therapy for proteinuria.赖诺普利和氯沙坦治疗蛋白尿期间的急性肾衰竭
Pharmacotherapy. 2006 Sep;26(9):1348-51. doi: 10.1592/phco.26.9.1348.
2
Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.血管紧张素受体阻滞剂与ACE抑制剂联合治疗蛋白尿性肾病：疗效和安全性数据的系统评价
Am J Kidney Dis. 2006 Jul;48(1):8-20. doi: 10.1053/j.ajkd.2006.04.077.
3
The implications of a growing evidence base for drug use in elderly patients Part 2. ACE inhibitors and angiotensin receptor blockers in heart failure and high cardiovascular risk patients.老年患者用药证据不断增加的影响 第2部分。心力衰竭和心血管高危患者使用的血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂
Br J Clin Pharmacol. 2006 May;61(5):502-12. doi: 10.1111/j.1365-2125.2006.02610.x.
4
Effect of angiotensin II type 1 receptor antagonism on endothelial function: role of bradykinin and nitric oxide.血管紧张素II 1型受体拮抗剂对内皮功能的影响：缓激肽和一氧化氮的作用
J Hypertens Suppl. 2006 Mar;24(1):S39-43. doi: 10.1097/01.hjh.0000220405.38622.23.
5
Pharmacotherapy review: Angiotensin receptor antagonists.药物治疗综述：血管紧张素受体拮抗剂
J Clin Hypertens (Greenwich). 2005 Nov;7(11):681-4. doi: 10.1111/j.1524-6175.2005.04135.x.
6
ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure).美国心脏病学会/美国心脏协会成人慢性心力衰竭诊断和管理指南2005年更新：美国心脏病学会/美国心脏协会实践指南工作组（更新2001年心力衰竭评估和管理指南写作委员会）报告
J Am Coll Cardiol. 2005 Sep 20;46(6):e1-82. doi: 10.1016/j.jacc.2005.08.022.
7
Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense?在全剂量血管紧张素转换酶抑制剂基础上加用血管紧张素受体阻滞剂：是有争议还是常识之举？
Eur Heart J. 2005 Nov;26(22):2361-7. doi: 10.1093/eurheartj/ehi454. Epub 2005 Aug 16.
8
Individual titration for maximal blockade of the renin-angiotensin system in proteinuric patients: a feasible strategy?蛋白尿患者中肾素 - 血管紧张素系统最大程度阻断的个体化滴定：一种可行的策略？
J Am Soc Nephrol. 2005 Mar;16 Suppl 1:S53-7. doi: 10.1681/asn.2004121074.
9
Dual blockade of the renin-angiotensin system: the ultimate treatment for renal protection?肾素-血管紧张素系统的双重阻断：肾脏保护的终极治疗方法？
J Am Soc Nephrol. 2005 Mar;16 Suppl 1:S34-8. doi: 10.1681/asn.2004110966.
10
The ONTARGET/TRANSCEND Trial Programme: baseline data.ONTARGET/TRANSCEND试验项目：基线数据。
Acta Diabetol. 2005 Apr;42 Suppl 1:S50-6. doi: 10.1007/s00592-005-0181-3.
Zotero 插件